Datamonitor Healthcare interviewed two ulcerative colitis (UC) experts, one based in Italy and the other in the US, to gauge their views on approved and late-stage pipeline drugs, treatment challenges and unmet needs and the future treatment of UC. The specific drugs discussed include alicaforsen, Entyvio / vedolizumab [TKPYY], etrolizumab [RHHBF], filgotinib [GILD], Humira / adalimumab [ABBV], Inflectra / infliximab biosimilar, LT-02 [NSRGY], Ozanimod [CELG], Remicade / infliximab [JNJ], Simponi (SQ) / golimumab [JNJ], Stelara / ustekinumab [JNJ] and Xeljanz / tofacitinib [PFE]. The two interviews were combined into a single report.

If you are a KOL Insight Subscriber, please access the first and second interview from our KOL Insight portal (Subscribers only).

Biomedtracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (858) 200-2357.

For our disclosures, please read the Biomedtracker Research Standards.